Myelofibrosis Care

CE

Redefining Myelofibrosis Care: Treatment Advances & Key Considerations for Managed Care Professionals

Pharmacists: 1.50 contact hours (0.15 CEUs)

Released: May 16, 2024

Expiration: May 15, 2025

Justin R. Arnall
Justin R. Arnall, PharmD, BCOP
Victoria Nachar
Victoria Nachar, PharmD, BCOP

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

Case 1: Patient With Newly Diagnosed MF



  • 72-yr-old woman initially presents with shortness of breath, fatigue, significant night sweating, and weight loss




  • Not considered a candidate for transplant

  • After a shared conversation, the patient has agreed with your recommendation for ruxolitinib therapy

What dose of ruxolitinib is recommended for this patient per the prescribing information?

2.

Case 2: Patient With MF (Second Line)



  • 68-yr-old woman diagnosed with PV in 2012; received therapy with ASA, hydroxyurea, and phlebotomy; history of irritable bowel syndrome

  • January 2023: Progressed to post-PV MF after presenting with erythrocytosis, splenomegaly, and B-symptoms 

    • Began ruxolitinib 10 mg BID and now disease is progressing; unable to tolerate a higher dose of ruxolitinib 

    • Has anemia requiring admissions and dizziness

    • TSS = 14




In your current practice what therapy would you recommend for this patient?

3.

Which of the following adverse events is NOT associated with momelotinib?